April 8, 2022
The Honorable Jan Schakowsky
2367 Rayburn House Office Building
Washington, DC 20515
Dear Representative Schakowsky,
On behalf of the National Committee to Preserve Social Security and Medicare’s millions of members and supporters, I write to endorse the Pharmaceutical Research and Transparency Act of 2022, which amends the Public Health Service Act and the Security Exchange Act to require pharmaceutical manufacturers to report their costs related to clinical trials and research and development. Your important bill creates a repository of cost data for drug clinical trials and requires drug manufacturers to report clinical trial costs in their annual securities filings.
We applaud your leadership in creating more transparency around costs of clinical trials and research and development costs.
Sincerely,
Max Richtman
President and CEO